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ABSTRACT 
ELUCIDATING THE ROLE OF INTERLEUKIN-17A IN  
WEST NILE VIRUS INFECTION 
by Dhiraj Acharya 
May 2017 
West Nile virus (WNV) is a neurotropic flavivirus of significant public health 
importance for which no therapeutics and vaccine are currently available. 
Interleukin-17A (IL-17A) is an inflammatory cytokine that regulates diverse 
immune functions, while its role is unclear in host’s immune response to WNV. 
Furthermore, CD8+ T cells are crucial components of immunity and play a vital 
role in recovery from WNV infection. Here, we report a previously unrecognized 
function of IL-17A in regulating CD8+ T cell cytotoxicity. We show that WNV 
induces the expression of IL-17A in both mouse splenocytes and human 
peripheral blood mononuclear cells cultured in vitro, and in plasma of WNV-
infected mice and humans. In a mouse model of WNV infection, we demonstrate 
that IL-17A deficient mice (Il17a-/-) are more susceptible to WNV and develop a 
higher viral burden compared to wild-type (WT) mice. Interestingly, the CD8+ T 
cells isolated from WNV-infected Il17a-/- mice are less cytotoxic and express 
lower levels of cytotoxic mediator genes, which can be restored by supplying 
recombinant IL-17A in vitro and in vivo. Moreover, treatment of WNV-infected 
mice with recombinant IL-17A, as late as day 6 post-infection, significantly 
reduces viral burden and increases survival, suggesting a therapeutic potential of 
IL-17A. In conclusion, we demonstrate a novel function of IL-17A in promoting 
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CD8+ T cell cytotoxicity against WNV infection, which may have broad 
implications in other microbial infections and cancers. 
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CHAPTER I - INTRODUCTION 
1.1 West Nile Virus 
West Nile virus (WNV), a neurotropic single-stranded RNA virus belonging 
to flaviviridae family, is generally transmitted to human by an infected mosquito 
bite, primarily of Culex species (Colpitts et al., 2012; Kuno and Chang, 2005). 
However, WNV can also be transmitted through other less frequent transmission 
routes, including blood transfusion (Pealer et al., 2003; Stramer et al., 2005), 
organ transplantation (Centers for Disease and Prevention, 2009), breastfeeding 
(Blazquez and Saiz, 2010), and congenital infections (Alpert et al., 2003). WNV 
infection in human can cause fever and may result in injury and death of 
neurons, the latter can lead to various neurological manifestations, such as 
encephalitis, flaccid paralysis, meningitis, chronic neurologic sequelae and 
possibly death, particularly in the elderly and immunocompromised individuals 
(Colpitts et al., 2012; Hayes et al., 2005; Samuel and Diamond, 2006). 
Structurally, WNV is an enveloped virus with 50 nm diameter, which 
comprises an icosahedral nucleocapsid surrounded by a host-derived lipid 
envelope (Mukhopadhyay et al., 2003). The WNV genome contains a capped, 
single-stranded, and plus-sensed RNA genome of approximately 11 Kb in size. 
The WNV genome translates to a polyprotein precursor, which undergoes 
posttranslational processing by viral and cellular proteases to generate three 
structural (capsid [C], premembrane [PrM], and envelope [E]), and seven non-
structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5). Among 
these proteins, the structural proteins form the structure of virion, whereas the 
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non-structural proteins are essential in genome replication, virion assembly, and 
viral pathogenesis (Chung et al., 2006; Liu et al., 2006; Mukherjee et al., 2011a). 
1.1.1 WNV Is a Major Public Health Problem 
 WNV was first discovered in Uganda about 80 year ago and primarily 
maintained in a mosquito-bird-mosquito transmission cycle (Colpitts et al., 2012). 
Until 1990’s it caused several sporadic outbreaks of minor public health 
importance in Africa, Asia, Europe and the Middle East with a limited capacity to 
cause neuroinvasive diseases (Draganescu, 1979; Kramer et al., 2008). The first 
report of neuroinvasive cases of WNV in Algeria in 1994 (Le Guenno et al., 
1996), and a huge report of neurological impairments during subsequent WNV 
outbreaks in South-East of Romania (Cernescu et al., 1997), and other parts of 
southern Europe (Hubalek and Halouzka, 1999) brought this virus into a real 
public health concern. In northern hemisphere, WNV was first identified in New 
York in 1999 (Hayes, 2001; Mostashari et al., 2001), which subsequently spread 
throughout the USA within a few years (Benjelloun et al., 2015).  
Currently, WNV is causing endemic diseases throughout the North 
America and has a wide geographical distribution in all continents of globe 
except Antarctica (Benjelloun et al., 2015). In the US alone, there have been over 
40,000 cases of WNV reported between 1999 and 2014, out of which about 45% 
were classified as neuroinvasive cases (CDC, 2015). However, the actual burden 
of WNV is likely much higher than previously thought because only a proportion 
(about 20%) of infected individual develop a clinical disease and a majority of 
infected individuals remain asymptomatic (Mostashari et al., 2001). It has been 
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recently estimated that over 3 million individuals have been infected with WNV in 
the USA alone, out of which about 780,000 had a symptomatic illness (Petersen 
et al., 2013). Considering the worldwide circulation of WNV and supportive 
evidence of its capacity to change pathogenicity and transmission potential 
(Davis et al., 2005; Ebel et al., 2004; Moudy et al., 2007; Prow et al., 2014; van 
den Hurk et al., 2014), there is an urgent need to develop a safe and effective 
antiviral drug or vaccine against WNV infection (Martina et al., 2010). However, 
no licensed antiviral drug or vaccine is currently available for WNV infection in 
humans.  
1.1.2 Pathogenesis of WNV Infection Is Not Well Understood 
After a bite of WNV-infected mosquito inoculates infectious viruses into 
human skin, WNV first infects skin-resident cells such as dendritic cells 
(Langerhans cells) and keratinocytes. Infected dendritic cells can carry the 
viruses to draining lymph nodes, after which WNV circulates through lymphatic 
systems and enters the blood stream (Lim et al., 2011; Ye et al., 2011). WNV can 
infect various cells including macrophages, neutrophils, and other leukocytes 
leading to development of a transient viremia. Subsequently, WNV can 
disseminate to peripheral organs, such as liver and spleen, and then to the brain 
and spinal cord. In most of the immune-competent individuals, WNV symptoms 
range from unapparent infection to mild febrile illness (Colpitts et al., 2012). In a 
few symptomatic cases, particularly in the elderly and immunocompromised 
individuals, WNV can cause injury and apoptosis of neuron, which can potentially 
cause various neurological impairments and death (Colpitts et al., 2012). Viral 
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entry into the brain is considered a hallmark of WNV pathogenesis and disease 
severity. Although the mechanism of neurotropism and how WNV enters the 
central nervous system (CNS) is not clearly understood, hematogenous entry via 
disrupted blood-brain barrier (BBB) and transneural entry via retrograde axonal 
transport have been suggested to play a role (Suen et al., 2014; Suthar et al., 
2013).  
1.1.3 Host’s Immunity Is Crucial in WNV Recovery 
WNV can infects various type of immune cells and strongly activates host 
immune responses, which play important roles in controlling viremia, reducing 
viral dissemination to the CNS, and recovery from the disease (Samuel and 
Diamond, 2006).  Clinical reports of WNV-infected human cases along with 
research using mouse models or in vitro approaches have identified critical roles 
of several components of immune system in WNV infections (Arjona et al., 2011; 
Suthar et al., 2013). In brief, type-I interferon (IFNs) (Lazear et al., 2011; Samuel 
and Diamond, 2005), the complement system (Mehlhop and Diamond, 2006), 
and humoral immunity (Diamond et al., 2003a; Diamond et al., 2003b) limit 
viremia and control WNV dissemination to CNS. Similarly, components of cell-
mediated immunity, including CD4+ (Sitati and Diamond, 2006) and CD8+ 
(Shrestha and Diamond, 2004) T cells, have been shown to clear WNV from the 
CNS, limit viral persistence, and facilitate recovery. In contrast, the roles of 
neutrophils, NK cells, and γδ-T cells are still unclear (Bai et al., 2010; Shrestha et 
al., 2006a; Welte et al., 2008). Cytokine signaling of interleukin (IL)-23 (Town et 
al., 2009), interferon-γ (IFN-γ)(Shrestha et al., 2006b), and IL-1β (Ramos et al., 
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2012) have been shown to protect against WNV infection, while cytokine such as 
IL-10 (Bai et al., 2009) and IL-22 (Wang et al., 2012) have been shown to favor 
WNV pathogenicity. The role of tumor necrosis factor-α (TNF-α) still remains 
elusive (Shrestha et al., 2008b; Wang et al., 2004a). However, the role of several 
other components of immune system yet remains unknown and the mechanism 
of WNV pathogenesis, including its tropism to neurons and CNS invasion, 
remains unclear. In addition, we have limited knowledge on viral or host factors 
that contribute to imbalance between viral pathology and host to WNV infection. 
1.2 Interleukin-17A and Its Signaling 
IL-17A, a major cytokine of IL-17 family (IL-17A, B, C, D, E, and F), was 
discovered in 1993 as the cytotoxic T-lymphocyte antigen-8 (Rouvier et al., 
1993). CD4+ Th17 (Th-17) cells are one of the most common sources of IL-17A. 
Besides Th-17 cells, a wide variety of immune cells, including CD8+ T cells, γδ-T 
cells, and natural killer T (NKT) cells can also produce IL-17A under various 
pathological conditions (Gu et al., 2013). IL-17A signals through IL-17 receptor 
(IL-17R) complex composed of IL-17RA and IL-17RC subunits (Ho and Gaffen, 
2010). Both subunit of IL-17R complex encode a SEFIR (Similar Expression to 
Fibroblast growth factor genes and IL-17 Receptor) domain that mediates various 
downstream signaling events through the adaptor protein NF-κB activator-1 
(ACT1) (Gaffen, 2009; Ho and Gaffen, 2010). Specifically, the ACT1 recruits to 
IL-17R through interaction with SEFIR domain and activates TNF receptor-
associated factor-6 (TRAF6) and TRAF3, which are essential upstream 
activators of the nuclear factor- B (NF- B) signaling pathway. In addition, ACT1 
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is also required for IL-17A mediated stabilization of mRNAs that encode several 
chemokines and cytokines. Moreover, IL-17A also signals through ACT1 
independent pathway by activation of extracellular signal-regulated kinase (ERK) 
(Ho and Gaffen, 2010). 
1.2.1 IL-17A Regulates Diverse Immune Functions 
The finding that IL-23 drives expression of IL-17 in CD4+ T cells led to the 
realization of a new paradigm that many functions formerly attributed to CD4+ Th-
1 cells were in fact mediated by a distinct, IL-17-producing T cell subset known 
as Th-17 cells (Aggarwal et al., 2003; Langrish et al., 2005). It is now well 
established that IL-1β, IL-6, TGF-β, and IL-21 drive development, while IL-23 
stabilizes Th-17 cells (Korn et al., 2007; Nurieva et al., 2007; Sutton et al., 2006; 
Zhou et al., 2007).  
IL-17A signaling regulates diverse immune functions including the 
expression of various inflammatory cytokines, chemokines and antimicrobial 
peptide, activation and recruitment of leukocytes, and production of antibodies 
(Gu et al., 2013; Song and Qian, 2013) during infection and immunity. For 
example, IL-17A has often been described as a mediator of inflammation 
(Witowski et al., 2004) with prominent roles in allergic and autoimmune diseases 
including multiple sclerosis (McFarland and Martin, 2007; Zepp et al., 2011), 
rheumatoid arthritis (van den Berg and Miossec, 2009), psoriasis (Raychaudhuri, 
2013), asthma (Newcomb and Peebles, 2013), and Crohn’s disease (Siakavellas 
and Bamias, 2012). Similarly, IL-17A also plays protective roles against some 
bacterial and fungal infections. For instance, IL-17A may enhance neutrophil 
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recruitment and protect against bacterial and fungal pathogens such as 
Klebsiella pneumonia and Escherichia coli (Happel et al., 2005; Shibata et al., 
2007; Ye et al., 2001), Listeria monocytogenes (Hamada et al., 2008), 
Mycobacterium tuberculosis (Witowski et al., 2004), Francisella tularensis (Lin et 
al., 2009), Chlamydia muridarum (Zhang et al., 2009), Candida albicans (Conti et 
al., 2009; Huang et al., 2004) and Pneumocystis carinii (Rudner et al., 2007). 
Conversely, IL-17A signaling has been suggested to facilitate toxoplasmosis 
(Guiton et al., 2010) and certain fungal infections (Zelante et al., 2007). 
1.2.2 Role of IL-17A in Viral Infections Is Unclear 
The IL-17A has been originally identified as a homolog of virally encoded 
ORF13 gene of herpesvirus saimiri (Yao et al., 1995). This discovery generated 
interest to study the role of this cytokine in viral infection. It has been 
demonstrated that genetically constructed vaccinia virus (VV) expressing IL-17A 
(VVIL-17A) caused more severe disease in mice (Patera et al., 2002), but VVIL-17A 
was also reported less virulent and IL-17 deficient (Il17a-/-) mice were more 
susceptible to VV infection (Kohyama et al., 2007). Thus, the role of IL-17A 
during VV infection remains inconclusive. 
Interestingly, it has been reported that type I IFNs potently suppress IL-
17A expression (Curtis et al., 2009; Tilg et al., 2009), which further makes the 
functional role of IL-17A during viral infections more complex to understand. In 
most of the viral infections, type I IFN-mediated antiviral response primarily 
occurs during early phase of infection (Lazear et al., 2011; Pinto et al., 2011). It 
can be speculated that the IL-17A functions may be more dominant in the later 
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phase of infection when type I IFN expression levels become low. It has been 
shown that viral infections can induce expression of IL-17A (Mukherjee et al., 
2011b; Town et al., 2009; Wang et al., 2013), which has been implicated in 
priming T cell responses during lymphocytic choriomeningitis virus (LCMV) 
hepatitis (Jie et al., 2014) and mediating immunopathogenicity of viral infections 
such as influenza virus (Crowe et al., 2009), respiratory syncytial virus (de 
Almeida Nagata et al., 2014; Mukherjee et al., 2011b), murine encephalomyelitis 
virus (Hou et al., 2009) and hepatitis B virus (Wang et al., 2013). However, the 
role of IL-17A in WNV infection in not clearly understood.  
1.3 Possible Implication of IL-17A in WNV Infection 
It has been previously reported that WNV infection induces Toll-like 
receptor-7 (TLR7) dependent production of IL-23 in mice (Town et al., 2009). IL-
23 is known as a prime regulator for stabilization and maintenance of CD4+ Th-17 
cells, which are the major cell type secreting IL-17A (Aggarwal et al., 2003; 
McGeachy et al., 2009; Stritesky et al., 2008). Thus, it is likely that WNV infection 
induces IL-17A expression, which may play a role in WNV immunity. The 
following literature provides strong evidence for possible involvement of IL-17A 
signaling during WNV infection. 
1.3.1 IL-17A Is Crucial in the CNS Inflammation 
WNV primarily targets neurons and causes inflammation in the CNS, 
which play important role in its pathogenesis. Astrocytes and microglia up-
regulate the expression of functional IL-17A receptor and respond to this cytokine 
during brain inflammatory conditions (Das Sarma et al., 2009). In addition, IL-17A 
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is also described as a mediator of CNS inflammation (McFarland and Martin, 
2007; Zepp et al., 2011) and suggested as a blood-brain-barrier permeability 
factor (Kebir et al., 2007). Therefore, the WNV pathogenesis and host’s immune 
response in the CNS are likely impacted by IL-17A. 
1.3.2 IL-17A May Control Host’s Immunity to WNV Infection 
Considering the role of IL-17A in regulating diverse immune function, it 
can be speculated that this cytokine may play an important role in WNV 
immunity. For instance, IL-17A has been shown to regulate the expression of 
other cytokines including IL-1β, IFN-γ and TNF-α (Maione et al., 2009; Song and 
Qian, 2013), infiltration of leukocytes, and production of antibodies (Yao et al., 
1995; Yuan et al., 2010). As these cytokines are previously described to 
modulate immunity to WNV (Ramos et al., 2012; Shrestha et al., 2006b; 
Shrestha et al., 2008b; Wang et al., 2004a), one can expect possible involvement 
of IL-17A in WNV immunity. Moreover, brain-infiltrating leukocytes are crucial in 
clearance of WNV (Bai et al., 2010; Shrestha and Diamond, 2004), which can be 
potentially controlled by IL-17A signaling. Furthermore, the humoral immune 
response, which plays an important role in controlling viremia and WNV 
dissemination to CNS (Diamond et al., 2003a), can be potentially regulated by IL-
17A (Yuan et al., 2010).  
Among the CNS-infiltrating leukocytes, CD8+ T cells play crucial role in 
WNV immunity (Shrestha and Diamond, 2004, 2007; Shrestha et al., 2012; 
Shrestha et al., 2006a). Although the relation between IL-17A signaling and CD8+ 
T cell cytotoxicity is not yet studied, several literatures support this novel axis 
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may play a role in WNV and other viral infections. First, both Th-17 cells and γδ-T 
cells, the major cells that produce IL-17A, have been previously shown to 
promote CD8+ T cell cytotoxicity during intracellular infections (Hamada et al., 
2009; Xu et al., 2010). Second, the Th-17 cells and IL-17 have also been shown 
to control CD8+ T cell function in autoimmune diseases (Ankathatti Munegowda 
et al., 2011a). Third, the CD8+ T cells have a crucial role in clearance of tumor 
cells (Benchetrit et al., 2002; Martin-Orozco and Dong, 2009). Several studies 
also demonstrated the expression of IL-17A in tumor cells (Benchetrit et al., 
2002; Martin-Orozco and Dong, 2009). Interestingly, it has been shown that Th-
17 cell and IL-17A induce cytotoxic function of CD8+ T cells and control tumor 
progression (Benchetrit et al., 2002; Martin-Orozco and Dong, 2009), however, 
the mechanism for this IL-17A-CD8+ T cell axis remains yet unknown. Therefore, 
considering the crucial role of CD8+ T cells in WNV immunity, WNV is a suitable 
model to study IL-17A-CD8+ T cell axis. 
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CHAPTER II – SIGNIFICANCE, HYPOTHESIS, AND INNOVATION 
2.1 Significance 
WNV infection is a significant public health problem, for which no 
therapeutics or vaccine are currently available. In addition, IL-17A and CD8+ T 
cells regulate diverse immune functions during microbial infections, 
malignancies, and autoimmune diseases. In this study, we studied the function of 
IL-17A in WNV immunity and identified a potential therapeutic role of IL-17A in 
facilitating WNV clearance by promoting CD8+ T cells cytotoxicity. Further 
understanding of the interplay between CD8+ T cells and IL-17A axis may lead to 
identification of novel therapeutic strategies. Moreover, this novel function of IL-
17A may have broad implications in deciphering the immunopathology of other 
viral infections and malignancies, where CD8+ T cells functions are crucial. 
2.2 Hypothesis 
Despite intensive research over the past 15 years, WNV pathogenesis 
and host’s immune response still remains unclear. IL-17A, a major cytokine in the 
IL-17 family regulates diverse immune functions including the expression of 
various inflammatory cytokines and chemokines, activation and recruitment of 
leukocytes, and production of antibodies (Gu et al., 2013; Song and Qian, 2013). 
Moreover, IL-17A has often been described as a mediator of inflammation 
(Witowski et al., 2004) with an important role in allergic and autoimmune 
diseases (McFarland and Martin, 2007; Newcomb and Peebles, 2013; 
Raychaudhuri, 2013; van den Berg and Miossec, 2009; Zepp et al., 2011), 
malignancies (Martin-Orozco and Dong, 2009; Murugaiyan and Saha, 2009), and 
 12 
infections (Conti et al., 2009; Hamada et al., 2008; Happel et al., 2005; Huang et 
al., 2004; Lin et al., 2009; Rudner et al., 2007; Shibata et al., 2007; Ye et al., 
2001; Zhang et al., 2009). However, the role of IL-17A signaling is not clear 
during viral infections and has been previously studied in WNV infection. As we 
described in the introduction (section 1.7), there are several evidences 
suggesting a possible role of IL-17A in controlling host’s immune response to 
WNV. Therefore, we hypothesized that IL-17A may play a crucial role in WNV 
immunity. In this study, we tested this hypothesis under following four specific 
aims. 
Specific Aim 1: Study the expression of IL-17A during WNV infection in 
vitro and in vivo. It has been previously reported that TLR7 mediates IL-23-
dependent protective immune responses against WNV infection in mice (Town et 
al., 2009). IL-23 is known as a prime regulator for stabilization and maintenance 
of CD4+ Th-17 cells, which are the major cell type secreting IL-17A (Aggarwal et 
al., 2003; McGeachy et al., 2009; Stritesky et al., 2008). Since IL-17A is also 
described as a mediator of CNS inflammation (McFarland and Martin, 2007; 
Zepp et al., 2011), and a factor contributing to blood-brain-barrier permeability 
(Kebir et al., 2007), we asked if WNV induces IL-17A production and whether it 
involves IL-23 signaling. 
Specific Aim 2: Study the role IL-17A in WNV immunity in a mouse model. 
Based on the literature, it is likely that IL-17A may play either protective or 
pathogenic role during WNV infection. To dissect this question, we used a mouse 
 13 
model of WNV infection and compared survival and viral burden of WNV infected 
IL-17A deficient (Il17a-/-) and WT control mice.  
Specific Aim 3: Study the immune functions of IL-17A during WNV 
infection. IL-17A has been shown to recruit leukocytes (Happel et al., 2005; Ye et 
al., 2001), control cytokine and chemokine expression (Maione et al., 2009; Song 
and Qian, 2013), and regulate humoral immune response (Grund et al., 2012; 
Tarlinton, 2008; Yuan et al., 2010). Under this specific aim, we asked how 
various immune functions were controlled by IL-17A during WNV infection. 
Specific Aim 4: Study the mechanism of IL-17A mediated regulation of 
WNV immunity. From Aim 3, we identified a novel function of IL-17A in regulation 
of CD8+ T cell cytotoxicity. Under Aim 4, we studied the mechanism of IL-17A 
mediated control of CD8+ T cells cytotoxicity and its potential therapeutic role 
against WNV infection. 
2.3 Innovation 
Cytotoxic CD8+ T cells are important component of immunity, particularly 
in clearance of intracellular infections and tumors. One of the effector 
mechanisms used by these cells is cytotoxic killing of target cells. However, 
regulators of CD8+ T cell cytotoxicity, in particular, the expression of cytotoxicity 
mediators in these cells is poorly understood. In addition, functions of several 
molecules expressed in CD8+ T cells remain uncharacterized. One such 
molecule is the IL-17A receptor (IL-17R), which is expressed on the surface of 
CD8+ cells (Lindemann et al., 2008; Yao et al., 1995). In additions, subsets of 
CD8+ cells can produce IL-17A (Hamada et al., 2009). Considering the role of IL-
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17A in regulation of diverse immune functions during microbial infections, 
malignancies, and autoimmune diseases, it is likely that IL-17A signaling may 
play a role in biology of CD8+ T cells. CD8+ T cells are particularly important in 
controlling viral infections and have been shown to play a crucial role in 
clearance of WNV infection (Shrestha and Diamond, 2004). In this study, we 
studied the role of IL-17A in a mouse model of WNV infections and discovered a 
novel, previously unrecognized, function of IL-17A in promoting CD8+ T cells 
cytotoxicity. 
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CHAPTER III – EXPERIMENTAL APPROACHES 
3.1 Ethics Statement and Biosafety 
Written informed consent was obtained from all human volunteers and 
human WNV cases prior to their enrollment in this study. The protocol for human 
subject has been reviewed and approved by the University of Southern 
Mississippi (USM) Institutional Review Board (IRB, protocol # CH-R11120601, 
Appendix A). All animal experimental procedures were reviewed and approved 
by the Institutional Animal Care and Use Committee at USM (protocol 
#12041201, Appendix A). All the in vitro experiments and animal studies 
involving infectious WNV were performed by the certified personnel in biosafety 
level 3 (BSL3) or animal biosafety level 3 (ABSL3) laboratories following 
standard biosafety protocols approved by USM Institutional Biosafety Committee.  
3.2 Virus Stock and Animal Studies 
Low-passaged WNV isolate CT2741 (Anderson et al., 1999) was provided 
by Dr. John F. Anderson at the Connecticut Agricultural Experiment Station. Low-
passaged CHIKV LR OPY1 2006 strain was provided by Dr. Robert B. Tesh at 
the University of Texas Medical Branch. WNV and CHIKV stocks used in this 
study were prepared by propagating the viruses in Vero cells through a single 
passage and titrated in Vero cells by a plaque-forming assay as previously 
described (Bai et al., 2005). Vero cells (ATCC CCL-81) were cultured in a 37°C 
incubator with 5% CO2 in Dulbecco’s modified Eagle medium (DMEM, Life 
Technologies) supplemented with 10% fetal bovine serum (FBS). Interleukin-17A 
deficient (Il17a-/-) mouse breeding pairs (C57BL/6J background) were provided 
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by Dr. Richard A. Flavell at the Yale University School of Medicine and wild-type 
(WT) control mice (C57BL/6J) were purchased from The Jackson Laboratory 
(Bar Harbor, ME). IL-23 deficient (Il23p19-/-) breeding pairs on a mixed C57BL/6 
× 129 background were obtained from the Mutant Mouse Regional Resource 
Center (MMRRC). Mice were housed under standard conditions in the animal 
facility at USM. Gender-matched and 7 to 9 weeks old Il17a-/- and WT control 
mice were infected with 1,000 plaque forming units (PFUs) of WNV by i.p. 
injection in 100 µl of phosphate buffer saline (PBS) containing 5% gelatin (Town 
et al., 2009). For footpad inoculation, 100 PFU of WNV in 50 µl PBS containing 
1% FBS was injected into the mouse footpad after isofluorane anesthesia (Bai et 
al., 2009). Infected animals were observed twice daily for up to 21 days for 
morbidity and mortality. 
3.3 Cell Culture and In Vitro Infection 
Human peripheral blood mononuclear cells (hPBMCs) were isolated from 
blood of healthy human volunteers using Ficoll-paqueTM PLUS (GE healthcare). 
To isolate murine splenocytes, healthy C57BL/6J mice (7-week old) were 
euthanized and spleens were collected to make single cell suspension. After red 
blood cell lysis, both mouse splenocytes and hPBMCs were purified and cultured 
in the Dulbecco’s modified Eagle medium (DMEM, Life Technologies) 
supplemented with 10% FBS, 2 mM L-glutamine, and 1% non-essential amino 
acids. Cells were infected with WNV (MOI = 0.1, 1 or 5) and collected in 
TRIreagent (Molecular Research Center) at 24 h and 48 h for total RNA 
extraction.  
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3.4 Quantitative Polymerase Chain Reaction (qPCR) 
Total RNA was extracted from cells or animal tissues (i.e. blood, spleen, 
and brain) using the TRIreagent or RNeasy kit with on-column DNA digestion 
(Qiagen). First-stranded complementary DNA (cDNA) was synthesized using the 
iSCRIPTTM cDNA synthesis kit (Bio-Rad). WNV-envelope (WNVE) RNA copy 
numbers were quantified using probe-based qPCR and normalized to cellular β-
actin gene, as previously described (Bai et al., 2005). qPCR assays for cytokine, 
chemokine, and other immunological marker genes were performed using SYBR 
Green supermix (Bio-Rad) and data are presented either as the relative fold 
change (RFC) by ΔΔCT method using β-actin as a housekeeping gene or as a 
copy number ratio of target gene to cellular β-actin. Primer sequences for mice 
(Bai et al., 2005) and human (Kozaci et al., 2007) β-actin are previously 
described. Primers sequences for human Il17a (F, 5’-
TGTGATCTGGGAGGCAAAGT-3’; R, 5’-GATCTCTTGCTGGATGGGGA-3’), and 
mouse Il17a (F, 5’-TCTCCACCGCAATGAAGACC-3’, R, 5’-
TTTCCCTCCGCATTGACACA-3’); perforin-1 (F, 5'-
TGTTCCTCCTGGGCCTTTTC-3'; R, 5'-CCATACACCTGGCACGAACT-3'), 
granzyme-A (F, 5'-CACGTGAGGGGGATCTACAAC-3'; R, 5'-
TCTCCCCCATCCTGCTACTC-3'), granzyme-B (F, 5'-
TGCTACTGCTGACCTTGTCTC-3'; R, 5'-CCATGTAGGGTCGAGAGTGG-3'), 
fasL (F, 5'-GAACTGGCAGAACTCCGTGA-3'; R, 5'-
TGAGTGGGGGTTCCCTGTTA-3'), Ifn-α (F, 5'-TTCCCCTGACCCAGGAAGAT-
3'; R, 5'-CTTCTGCTCTGACCACCTCC-3'), Ifn-β (F, 5'-
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TGTCCTCAACTGCTCTCCAC-3'; R, 5'-ATCTCTGCTCGGACCACCAT-3'), Act-1 
(F, 5’-GAGGACGAGCATGGCTTACA-3’; R, 5’-TGGCATTTGGGAAGAGCACA -
3’) were designed using NCBI’s primer designing tool and synthesized by 
Integrated DNA Technologies. 
3.5 Enzyme Linked Immunosorbent Assay (ELISA) 
IL-17A, IFN-β, IL-1β, IFNγ, TNFα, IL-6, IL-10, IL-12p40, and anti-WNV-E 
IgM antibody in plasma of WNV-infected mice (1,000 PFU, i.p.) were measured 
using ELISA kit (R&D Systems) following manufacturer’s instructions. Level of IL-
17A in culture media, and sera of human WNV cases and healthy controls was 
measured by ELISA kit from Enzo Life Sciences. 
3.6 Confocal Microscopy 
Brains were collected from WNV-infected mice (1,000 PFU, i.p.) after 
intracardial PBS perfusion, fixed overnight in 4% PFA at 4°C, and cryoprotected 
in sucrose. Para-median sagittal sections (25 μm) of brain were pre-blocked for 
30 min at room temperature and then probed overnight at 4°C with a combination 
of primary antibodies against CD11b, CD45 and WNV antigen (anti-WNV 
antibody provided by John F. Anderson, other antibodies purchased from BD 
Biosciences). After a PBS wash, sections were probed with appropriate 
fluorescent labeled secondary antibodies for 1 h at room temperature, 
counterstained with DAPI (Invitrogen), and mounted in fluorescence mounting 
medium (ProLong Gold). Images were acquired in independent channels using a 
Nikon A1R confocal microscope. 
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3.7 Flow Cytometry 
Brains were collected from WNV-infected (1,000 PFU, i.p.) mice after 
intracardial PBS perfusion and processed into a single cell suspension. Brain 
leukocytes were isolated using a discontinuous Percoll gradient (GE Healthcare) 
and probed with CD45, CD4, CD8, and CD11b (BD Biosciences or eBioscience). 
After staining, cells were washed two times in flow cytometry buffer (FCB, PBS 
with 2% FBS) and fixed in 4% paraformaldehyde (PFA) for 15 minutes. For 
intracellular staining, cells were permeabilized and probed with antibodies 
against perforin, and granzyme A (eBioscience). Cells were then washed and re-
suspended in FCB. Data were acquired on a flow cytometer (BD LSRFortessa) 
and analyzed with FlowJo or FACSDivaTM software (BD Biosciences).  
3.8 CD8+ T cell Isolation and Cytotoxicity Assay 
Spleens were collected from WNV-infected (100 PFU, i.p.) mice at 10 
d.p.i.. Splenic CD8+ T cells were isolated by negative antibody selection with 
magnetic beads using the mouse CD8+ T Lymphocyte Enrichment Set-DM (BD 
Biosciences). Purity of CD8+ T cells was examined by flow cytometry after 
staining with fluorescent labeled anti-CD3 and anti-CD8 antibodies 
(eBioscience). Cytotoxicity of CD8+ T cells was measured as described 
previously (Shrestha and Diamond, 2004), with some modifications. Briefly, 
purified CD8+ T cells (~ 80-90% purity) were co-cultured for 4 h in 96-well plates 
with target cells expressing the ectodomain of WNV-E (MC57GLWNV-E) or control 
cells containing the expression vector (MC57GLvector) (gifted by Dr. Michael S. 
Diamond) with effector to target cell ratios of 50:1. CD8+ T cell cytotoxicity was 
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measured using a LDH Cytotoxicity Detection Kit (Thermo Scientific). Transcripts 
of perforin-1, granzyme A, granzyme B and Fas-ligand (FasL) genes in purified 
CD8+ T and CD8- cells were measured by qPCR, as described above. 
3.9 Ex Vivo and In Vivo IL-17A Treatment Assays 
For ex vivo studies, splenocytes were isolated from WNV-infected (100 
PFU, i.p.) mice at 8 d.p.i. and splenic CD8+ T cells were purified as described 
above. In some experiments, CD4+ T cells were depleted from splenocytes using 
CD4 Magnetic Particles - DM (BD Biosciences). Splenocytes, purified CD8+ T 
cells, or CD4- splenocytes were cultured for 24 h in the presence of mouse 
recombinant IL-17A (50 ng/ml, eBioscience). In some experiments, splenocytes 
were cultured for 24 h in the presence of mouse recombinant IL-17A (50 ng/ml) 
and subjected to CD8+ T cell purification. Expression of perforin-1, granzyme A, 
granzyme B and FasL in splenocytes, CD8+ T cells, and splenic CD8- cells were 
measured by qPCR, as described above.  
For in vivo IL-17A treatment and survival studies, WT female mice (8-
week old) were inoculated with WNV (100 PFU) via i.p. route. At day 6 p.i, mice 
were treated (2.5 μg/mouse) with i.p. administration of carrier-free mouse 
recombinant IL-17A (eBioscience) or PBS, and monitored daily for mortality and 
morbidity for up to 21 days. Randomly selected mice were euthanized at day 8 
p.i. and WNV burden in brain and the expression of the cytotoxic mediators in 
splenic CD8+ and CD8- T cells were measured by qPCR as described above. 
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3.10 Statistical Analyses 
Data were analyzed using two-tailed student’s t-test or analysis of 
variance (ANOVA) in GraphPad Prism (GraphPad Software, version 6), with p < 
0.05 considered statistically significant. 
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CHAPTER IV – RESULTS 
4.1 WNV Induces Expression of Il17a and Il17ra in Humans 
We previously reported that WNV induces IL-23 production in mice in a 
TLR7-dependent manner (Town et al., 2009). Considering the role of IL-23 in 
Th17 cell stabilization and IL-17A production (Aggarwal et al., 2003), we 
hypothesized that IL-17A may play a role in WNV infection. To test this, we 
measured the expression of Il17a in human cells infected with WNV in vitro. 
Human peripheral blood mononuclear cells (hPBMCs) isolated from healthy 
human volunteers without a history of WNV infection were infected with WNV 
(MOI = 0.1 and 5) for 24 h and 48 h in vitro. WNV-infected hPBMCs were 
collected, total RNA isolated, and cDNA synthesis and quantitative real-time PCR 
(qPCR) was performed to measure transcripts of Il17a and cellular β-actin as a 
housekeeping gene. The qPCR results showed that Il17a gene expression was 
up-regulated in WNV-infected hPBMCs (Fig. 4.1A), which was further confirmed 
by measuring IL-17A production in hPBMC culture supernatants (Fig. 4.1B) by an 
enzyme-linked immunosorbent assay (ELISA). 
To relate these in vitro results to WNV infection in humans, we used 
ELISA to measure the production of IL-17A in the sera of human cases with 
active WNV infection (fever or neuroinvasive disease), with a history of recovered 
neuroinvasive WNV diseases, and healthy controls who have no history of WNV 
infection. The cases with active and long-standing history of neuroinvasive WNV 
diseases showed a trend of higher levels of IL-17A in sera compared to WNV 
fever cases and healthy controls (Fig. 4.1C), with no difference between the latter 
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two. These results demonstrate that WNV infection induces a production of IL-
17A in humans and suggest that this cytokine may play a role in WNV infection. 
 
Figure 4.1 WNV induces expression of Il17a and Il17ra in humans 
(A) Il17a transcripts were measured by qPCR and expressed as relative fold change (RFC) after normalization to cellular 
β -actin in human PBMCs infected with WNV for 24 h or 48 h. (B) IL-17A production in culture supernatant of WNV-
infected hPBMC was measured by ELISA. (C) Levels of IL-17A in sera of human WNV patients and healthy controls were 
measured by ELISA. Error bars represent standard error of mean (mean ± SEM). Data in A and B represent two 
independent experiments performed in triplicates and analyzed by a one-way ANOVA. “ns” denotes no significant 
difference (p > 0.05). 
4.2 WNV Induces Expression of Il17a and Il17ra in Mice 
To expand upon the findings from human samples, we used a mouse 
model of WNV infection because it reflects various aspects of human WNV 
disease (Bai et al., 2009; Bai et al., 2005; Town et al., 2009). Splenocytes 
isolated from C57BL/6J mice were infected with WNV (MOI = 0.1) in vitro for 24 h 
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and 48 h, and the expression of Il17a gene was measured by qPCR. Similar to 
hPBMC, Il17a transcript levels were up-regulated at both 24 and 48 h.p.i. in 
mouse splenocytes infected with WNV in vitro (Fig. 4.2A). 
 
Figure 4.2 WNV induces expression of Il17a and Il17ra in mice 
(A) RFC of Il17a transcripts after normalization to cellular β -actin in mouse splenocytes infected with WNV (MOI = 0.1) in 
vitro. (B to C) WT (C57BL/6) mice were infected with WNV (1,000 PFU, i.p.) and expression of Il17a (B) and Il17ra (C) 
transcripts were measured in brain tissue by qPCR. Error bars represent standard error of mean (mean ± SEM). Data in A 
represent two independent experiments performed in triplicates and analyzed by a one-way ANOVA. Data in B and C 
represent two independent experiments (n = 5 mice/group) and analyzed by two-tailed student's t-test; “ns” denotes no 
significant difference (p > 0.05). 
Since astrocytes, microglia, and brain infiltrating immune cells express 
functional interleukin-17 receptor A (IL-17RA) in brain inflammatory conditions 
(Das Sarma et al., 2009), we measured the expression of Il17a and Il17ra genes 
in brain of WNV-infected mice. For this, we infected a group of WT mice with 
WNV (1,000 PFU, i.p.), sacrificed them at various time points to collect brains, 
and measured levels of Il17a and Il17ra transcripts by qPCR. Indeed, there was 
a significantly up-regulated expression of both Il17a (Fig. 4.2B) and Il17ra (Fig. 
4.2C) genes in brain of WNV-infected mice compared to uninfected controls. 
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Collectively, these results indicate that WNV infection elevates the expression of 
both Il17a and Il17ra in mice, suggesting a possible role of IL-17A in WNV 
infection. 
4.3 WNV-mediated IL-17A Production Depends on IL-23 Signaling 
To further measure Il17a expression in mice and to test whether its 
production was IL-23 dependent, we intraperitoneally (i.p.) infected a group of 
wild-type (WT) littermates and IL-23 deficient (Il23p19-/-) mice (both are in mixed 
C57BL/6×129 background) with 1,000 plaque-forming units (PFUs) of WNV and 
measured IL-17A protein in plasma by ELISA. The results showed that WNV 
infection in mice induced IL-17A production (Fig. 4.3), but the level of this 
cytokine was undetectable in serum samples from mock-infected control mice 
(data not shown). 
 
Figure 4.3 WNV-mediate IL-17A response in a IL-23 dependent manner 
IL-17A production was measured in plasma of Il23p19-/- and their littermate WT control mice (7-9 week old) 
infected with WNV (1,000 PFU, i.p.) by ELISA. Error bars represent standard error of mean (mean ± SEM). 
Data represent two independent experiments (n = 3 to 5 mice/group) and analyzed by two-tailed student's t-
test; “ns” denotes no significant difference (p > 0.05). 
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Moreover, there was approximately 80% reduction in Il17a expression in 
Il23p19-/- mice at 3 days post infection (d.p.i), suggesting that IL-17A production 
during WNV infection in mice largely depends on IL-23 signaling (Fig. 4.3).  
4.4 IL-17A Protects Mice from Lethal WNV Infection 
To further investigate the role of IL-17A in WNV immunity, we used a 
mouse model of WNV encephalitis (Town et al., 2009). IL-17A deficient (Il17a-/-) 
and WT control mice (7-8 weeks old, sex-matched, strain C57BL/6J) were 
challenged via i.p. injection with 1,000 PFUs of WNV (Town et al., 2009), a dose 
that kills approximately 40 ~ 50% of WT animals. Morbidity and mortality was 
monitored twice daily for 21 days. We found strikingly greater susceptibility of 
Il17a-/- mice (20% survival) vs. WT control mice (60% survival) to lethal WNV 
infection (Fig. 4.4A). 
 
Figure 4.4 Il17a-/- mice are more susceptible to WNV infection 
Seven to nine weeks old WT (C57BL/6J) and Il17a-/- mice were infected with WNV via i.p. (1,000 PFU) or 
footpad (100 PFU) routes and monitored for mortality twice daily for 21 days; percentage (%) survival was 
compared using the Kaplan-Meier survival and log-rank test. (A) Survival curves after i.p inoculation, or (B) 
footpad inoculation. 
 
 
0 5 10 15 20
0
20
40
60
80
100
d.p.i
S
u
rv
iv
a
l 
(%
)
WT (n=28)
Il17a-/- (n=26)
i.p.
p < 0.01
0 5 10 15 20
0
20
40
60
80
100
d.p.i
S
u
rv
iv
a
l 
(%
)
WT (n=10)
Il17a-/-(n=8)
p < 0.01
footpad
 27 
To exclude the possibility of an inoculation route specific response, we 
also challenged Il17a-/- and WT mice with 100 PFUs of WNV via footpad (Bai et 
al., 2009), and performed survival analysis. Similar to the i.p. route, footpad 
inoculation showed that Il17a-/- mice were more susceptible to WNV infection 
(Fig. 4.4B). Together, these data suggest that IL-17A protects mice from lethal 
WNV infection. 
4.5 Mice Deficient in IL-17A Develop Higher Viral Burden 
To further expand the protective function of IL-17A in controlling WNV 
infection, we compared the virological profiles of WNV-infected Il17a-/- vs. WT 
mice in various tissues such as blood, spleen, liver and brain. Measurement of 
WNV viremia by qPCR revealed no difference at 2 d.p.i, however, a 3-fold 
increase in the transcript level of WNV envelope gene (WNVE) was observed at 
4 d.p.i. in WNV-infected Il17a-/- mice compared to WT controls (Fig. 4.5A). 
To assess the viral burden in peripheral organs, we sacrificed WNV-
infected mice, collected liver, spleen and brain samples at the selected time 
points, and performed a qPCR analysis. When compared to WT controls, we 
found approximately 2-fold increase in WNV-E transcripts in the liver of Il17a-/- 
mice (Fig. 4.5B). Consistent with the survival results, there were about 6-fold (at 
7 d.p.i.) and 30-fold (at 8 d.p.i.) increases in WNVE transcripts in the brain of 
WNV-infected Il17a-/- mice compared to WT controls (Fig. 4.5C). Although there 
was no difference in viral burden in spleens of WT vs. Il17a-/- mice at 4 d.p.i, 
Il17a-/- mice had significantly higher level (about 3-fold) of WNVE transcripts on 8 
d.p.i (Fig. 4.5D).  
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Figure 4.5 IL-17A deficiency results in deficient WNV clearance in mice 
Seven to nine weeks old WT (C57BL/6J) and Il17a-/- mice were infected with WNV via i.p. (1,000 PFU). qPCR was 
performed to measure WNV-E RNA in blood (A), liver (B), brain (C), and spleen (D) with viral burden expressed as the 
ratio of WNV-E RNA copies to cellular β-actin transcripts. The ratios of viral load between WT and Il17a-/- mice (mean ± 
SEM) were compared by two-tailed student's t-test; “ns” denotes no significant difference (p > 0.05). 
These data demonstrate that mice deficient in IL-17A develop higher viral 
burden in blood and liver at day 4, and have deficient clearance of WNV from 
brain and spleen at day 8 p.i., leading to greater WNV susceptibility. Collectively, 
these results indicate that IL-17A plays a protective role during WNV infection. 
4.6 CNS Leukocyte Slightly Elevates in WNV-infected Il17a-/- mice 
IL-17A has been shown to recruit leukocytes including neutrophils during 
microbial infections (Happel et al., 2005; Ye et al., 2001), and inflammatory 
conditions (Griffin et al., 2012). Since we observed a higher WNV burden in brain 
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of Il17a-/- mice, we asked if this was related to IL-17A-mediated control of 
leukocyte infiltration into brain during WNV infection. For this, we performed 
confocal microscopy to detect WNV-E antigen, CD45 (pan-leukocyte marker), 
and CD11b (microglial and macrophage marker) in brain sections of WNV-
infected Il17a-/- and WT mice sacrificed at 6 d.p.i. We focused on the olfactory 
bulb because we have shown that this brain region is most sensitive to WNV 
infection (Bai et al., 2009; Town et al., 2009; Wang et al., 2004a). Consistent with 
the qPCR measurement of WNVE RNA in brain tissue (Fig. 4.5C), the confocal 
imaging revealed more WNVE antigens in the brains of WNV-infected Il17a-/- 
mice compared to WT controls (Fig. 4.6A and B). Similar results were also 
obtained in other brain regions, including the cerebral cortex, brainstem, 
cerebellum, and striatum (data not shown). Unexpectedly, confocal imaging 
results showed more CD45+ (Fig. 4.6A) and CD11b+ leukocytes (Fig. 4.6B) in the 
brain of WNV-infected Il17a-/- mice than WT controls. 
To confirm these data and further quantify brain infiltrating immune cells, 
we performed flow cytometric analysis of brain leukocytes isolated from WT and 
Il17a-/- mice infected with 1,000 PFU (i.p.) of WNV for 6 days. We characterized 
CD45+, CD11b+, CD3+CD4+ and CD3+CD8+ cell populations, as previously 
described (Town et al., 2009). Consistent with the confocal imaging results, we 
observed a trend towards elevation of all leukocyte population in the brain of 
WNV-infected Il17a-/- mice compared to WT controls (Fig. 4.6C).  
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Figure 4.6 CNS leukocyte profile in WNV-infected Il17a-/- mice 
Seven to nine weeks old WT (C57BL/6J) and Il17a-/- mice were challenged with WNV (1,000 PFU) through 
i.p.. (A to B) PBS perfused brains were isolated on 6 d.p.i, and WNV antigen (green signal) and CD45 
(leukocyte common antigen, red, panel A) or CD11b (macrophage and microglia marker, red, panel B) were 
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detected by Nikon A1R confocal microscope (original magnification = 20X). DAPI (blue signal) was used as 
a nuclear counterstain; representative images are shown. (C) Brain leukocytes isolated on day 6 d.p.i. were 
characterized by flow cytometry after probing with antibodies against WNVE, CD45, CD4, CD8, and CD11b. 
Signal color used in dot plots and numbers representing the percentages of positive cells within gated 
populations are shown (right). Data represent two independent experiments (n = 5 mice per group for each 
experiment). 
To test whether the higher leukocyte infiltration into WNV-infected Il17a-/- 
mouse brains was affected by leukocyte expansion or differentiation in the 
periphery, we compared leukocyte populations in spleen of Il17a-/- and WT mice 
infected with WNV. There was no difference in leukocyte populations in spleens 
of WNV-infected Il17a-/- vs. WT mice (data not shown), suggesting that more 
leukocytes in brain may not be due to the possible effects of IL-17A on leukocyte 
expansion in the periphery. 
4.7 WNV-infected Il17a-/-  Mice Upregulate CCL5 
To further dissect the mechanism by which more leukocytes migrate into 
the brains of WNV infected Il17a-/- mice, we performed qPCR to measure the 
expression of selected chemokines genes (Cxcl1, Cxcl10, Ccl5) known to 
mediate recruitment of leukocytes. There was significantly elevated expression of 
Ccl5 (also known as RANTES) (Fig. 4.7A) and its receptor Ccr5 (Fig. 4.7B) in 
blood of WNV infected Il17a-/- mice at 4 d.p.i., but no difference in expression of 
other chemokines, such as Cxcl1 and Cxcl10 (data not shown). In addition, there 
was a significant increase of Ccl5 expression (Fig. 4.7C) in the brains of WNV-
infected Il17a-/- mice at 8 d.p.i., but no difference in expression of other leukocyte 
recruiting chemokines or chemokine receptors, such as Cxcl10 (Fig. 4.7D) and 
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Cxcr3 (Fig. 4.7E). These results may imply a link between deficient IL-17A and 
higher Ccl5 expression that may contribute to more leukocyte homing to the brain 
of Il17a-/- mice during the course of WNV infection. 
 
Figure 4.7 WNV infected Il17a-/- mice upregulate CCL5 
Expressions of Ccl5 (A) and Ccr5 (B) gene at the mRNA levels were measured by qPCR in the blood of 
WNV-infected mice at 2 and 4 d.p.i.. mRNA levels of Ccl5 (C), Cxcl10 (D) and Cxcr3 (E) genes were 
measured by qPCR in brain of WNV-infected mice at 8 d.p.i. Gene expression data were normalized to 
cellular β-actin mRNA and compared by two-tailed student's t-test; “ns” denotes no significant difference (p > 
0.05). 
4.8 IL-17A Does Not Affect Interferon Response and Inflammation 
WNV infection induces potent type I IFN responses in mice, which plays a 
critical role in controlling both viremia and encephalitis (Samuel and Diamond, 
2005). We tested whether deficient IL-17A alters type I IFN expression during 
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WNV infection by qPCR and ELISA. The qPCR results showed no difference in 
Ifn- expression in blood of Il17a-/- vs. WT control mice at 4 d.p.i. (Fig. 4.8A). 
Similarly, no difference in expression of Ifn- gene was observed in blood (Fig. 
4.8B), spleen (Fig. 4.8C), liver (Fig. 4.8D), and brain (Fig. 4.8E) samples from 
WNV-infected Il17a-/- vs. WT control mice measured at various time points. To 
further confirm these results, we also measured IFN- protein in plasma of WNV-
infected WT and Il17a-/- mice at 3 d.p.i. by ELISA and found no difference in IFN-
  expression (Fig. 4.8F). These results suggest that the type I IFNs response 
remains unaltered in Il17a-/- mice during WNV infection. 
IL-17A cause potent inflammation and regulate expression of several 
cytokines including IL-1β, IFNγ and TNFα (Maione et al., 2009; Song and Qian, 
2013). We assessed the possible role of IL-17A in inflammatory responses 
during WNV infection by measuring inflammatory cytokine expression in plasma 
by ELISA. Again, there was no difference in levels of IL-1β, IL-6, IL-10, IFN-γ, IL-
12 p40, and TNF-α in plasma from WNV-infected Il17a-/- vs. WT control mice at 
both 1 and 3 d.p.i. (Fig. 4.8G-L). In addition, no significant difference in 
expression of these cytokines was detected by qPCR in brain of WNV-infected 
Il17a-/- vs. WT control mice at 8 d.p.i. (data not shown). Collectively, these results 
demonstrate that higher viral load in Il17a-/- mice is likely not due to altered 
production of interferon and other inflammatory cytokines. 
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Figure 4.8 Antiviral and inflammatory responses of WNV-infected Il17a-/- mice 
Seven to nine weeks old WT (C57BL/6J) and Il17a-/- were infected with 1,000 PFU (i.p.) of WNV. Blood, plasma, and 
tissue samples were collected at the selected time points (d.p.i.) for cytokine and anti-WNV-E IgM measurement. 
Expression of interferon-  (Ifn- ) gene transcripts in blood (A), and expression of interferon- β (Ifn- β) gene transcripts in 
blood (B), spleen (C), liver (D), and brain (E) were measured by qPCR (normalized to cellular β -actin mRNA). (F to L) 
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Protein level of IFN-β  IL-1β  IL-6, IL-10, IFN- γ, IL-12p40, and TNF-α in plasma were measured by ELISA. Data 
(mean ± SEM) represent at least two independent experiments performed in triplicates and analyzed by two-tailed 
student's t-test; “ns” denotes no significant difference (p > 0.05). 
4.9 IL-17A Does Not Have a Direct Anti-WNV Effect 
We next asked if IL-17A has a direct antiviral activity against WNV 
infection, which has been shown for some other cytokines, such as TNF-α 
(Ruggiero et al., 1989; Shrestha et al., 2008b) and IL-6 (Moore et al., 2012). 
However, no effect in replication of WNV was observed in Raw 264.7 (mouse 
macrophage, Fig. 4.9A) and Neuro 2a (mouse neuroblast, Fig. 4.9B) cells that 
were pretreated with mouse recombinant IL-17A (1 to 100 ng/ml), suggesting that 
IL-17A may not have a direct antiviral effect against WNV replication. 
 
Figure 4.9 IL-17A does not directly control WNV replication 
Replication of WNV was analyzed by qPCR in Raw 264.7 (A) and Neuro 2a (B) cells that were pretreated with mouse 
recombinant IL-17A (1 to 100 ng/ml) for 6 h followed by infection with WNV (1 MOI) for 24 h. Data (mean ± SEM) 
represent at least two independent experiments performed in triplicates and analyzed by one-way ANOVA; “ns” denotes 
no significant difference (p > 0.05). 
4.10 IL-17A Does Not Control Humoral Immune Response 
Besides type I IFN, humoral immune response also plays an important 
role in clearance of WNV from the blood and peripheral organs and limits viral 
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dissemination to the CNS (Diamond et al., 2003a). Although the role of IL-17A in 
humoral immunity is not well understood, it has been shown that B cells express 
IL-17RA (Yao et al., 1995), whereas Th17 cells (major IL-17A producers) 
promote B cells to produce antibodies (Yuan et al., 2010). To test the possible 
effect of IL-17A in humoral immune responses during WNV infection, we 
compared WNV-E specific IgM antibody production in WNV-infected Il17a-/- and 
WT mice by ELISA. Both Il17a-/- and WT mice produced similar levels of anti-
WNV-E IgM when measured at 2, 3, and 5 d.p.i. (Fig. 4.10). These results 
demonstrate that higher viral load in Il17a-/- mice is likely, not due to altered 
antibody responses.  
 
Figure 4.10 WNV-mediated IL-17A does not affect antibody production 
Seven to nine weeks old WT (C57BL/6J) and Il17a-/- were infected with 1,000 PFU (i.p.) of WNV. Anti-WNV-E IgM 
antibody levels in plasma were measured by ELISA. Data (mean ± SEM) represent at least two independent experiments 
performed in triplicates and analyzed by two-tailed student's t-test; “ns” denotes no significant difference (p > 0.05). 
4.11 IL-17A Deficiency Causes the Reduced CD8+ T Cell Cytotoxicity 
Brain-infiltrating leukocytes play a vital role in clearing WNV from the CNS 
during WNV infection (Shrestha and Diamond, 2004; Sitati and Diamond, 2006; 
Town et al., 2009). In particular, CD8+ T cells are crucial for clearance of WNV 
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from the CNS and spleens (Shrestha and Diamond, 2004, 2007; Shrestha et al., 
2006a; Wang et al., 2004b). Despite a modest elevation trend of brain infiltrating 
CD8+ T cells in Il17a-/- mice, viral burden in the brains of these mice was higher 
than in WT controls (Fig. 4.5C). In addition, Il17a-/- mice were also deficient in 
clearing WNV from spleen (Fig. 4.5D). Therefore, we hypothesized that CD8+ T 
cells in Il17a-/- mice may be functionally defective in their ability to clear WNV-
infected target cells. To test this, we infected WT and Il17a-/- mice through i.p. 
with a sub-lethal dose of WNV (100 PFU) to prolong the course of WNV infection. 
This is important because CD8+ T cells play a major role in clearing WNV-
infected cells during the later phase (day 8 to 12) of infection (Shrestha and 
Diamond, 2004; Wang et al., 2004b), and most of Il17a-/- mice infected with a 
higher dose (e.g. 1,000 PFU or more) develop severe diseases and die during 
this time period. At 10 d.p.i., mice were sacrificed and splenic CD8+ T cells were 
purified using a negative antibody selection method. The purified effector CD8+ T 
cells were then co-cultured with the target cells (MC57GLWNV-E) or control cells 
(MC57GLvector) for 4 h. The target cells express the ectodomain of the WNVE in a 
pcDNA3.1 vector, while the control cells only express the parent vector (Shrestha 
and Diamond, 2004). The cytotoxicity of effector CD8+ T cells to WNV specific 
target cells was assessed by measuring the quantity of intracellular lactate 
dehydrogenase released into culture supernatants from the lysed target cells. 
Strikingly, the cytotoxicity assay showed about 2-fold reduction in cytotoxicity of 
CD8+ T cells isolated from WNV-infected Il17a-/- mice in comparison to WNV-
infected WT mice (Fig. 4.11A). These results demonstrate that CD8+ T cells from 
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Il17a-/- mice failed to mount an effective target cell-specific cytotoxic response 
during WNV infection. 
 
Figure 4.11 CD8+ T cells from Il17a-/- mice have reduced cytotoxicity 
Seven to nine weeks old WT (C57BL/6J) and Il17a-/- mice were infected with WNV at 100 PFU (i.p.) for 10 days. (A) 
Purified splenic CD8+ T cells were co-cultured with the target (MC57GLWNV-E) or control (MC57GLvector) cells at a 50:1 
effector/target ratio for 4 h and cytotoxicity was assayed by measuring the release of intracellular lactate dehydrogenase 
in culture supernatants. (B to E) RFC in transcripts of perforin-1 (B), granzyme A (C), granzyme B (D), and FasL (E) in 
indicated tissues of WT or Il17a-/ - mice were measured by qPCR (normalized to cellular β -actin mRNA). Data (mean ± 
SEM) represent three independent experiments (n = 3 mice/group). “ns” denotes no significant difference (p > 0.05). 
Cytotoxicity of CD8+ T cells employ granule (e.g., perforin and granzyme) 
exocytosis and Fas-Fas ligand (FasL) dependent mechanisms to kill target cells 
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(Shresta et al., 1998). To test whether IL-17A regulates the expression of 
cytotoxicity mediator genes, we performed qPCR assay in blood, spleen, liver, 
and brain of WT and Il17a-/- mice that were infected with WNV (100 PFU) for 10 
days. Interestingly, the expression levels of perforin-1 (Fig. 4.11B), granzyme A 
(Fig. 4.11C), granzyme B (Fig. 4.11D) and FasL (Fig. 4.11E) were significantly 
lower in most of these tissues collected from Il17a-/- mice compared to WT 
controls.  
4.12 Il17a-/- CD8+ T Cells Express Less Cytotoxicity Mediators 
Although CD8+ cells are the major cells that express these cytotoxic 
mediators, other cells, such as NK cells, may also express these genes and 
contribute to cytotoxic effector function by the mechanism similar to CD8+ T cells. 
To specifically test if the attenuated cytotoxicity of CD8+ T cells in Il17a-/- mice 
was due to the lower expression of these cytotoxic mediator genes, we 
performed qPCR to measure the expression of perforin-1, granzyme A, 
granzyme B and FasL in CD8+ T cells purified from spleens of WNV-infected WT 
and Il17a-/- mice at 10 d.p.i.. Consistent with the cytotoxicity assay results, the 
qPCR showed that CD8+ T cells isolated from the Il17a-/- mice have significantly 
reduced expression of perforin-1  (Fig. 4.12A), granzyme A (Fig. 4.12B), 
granzyme B (Fig. 4.12C) and FasL (Fig. 4.12D) compared to WT controls.  
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Figure 4.12 Il17a-/- CD8+ T cells express reduced cytotoxicity mediators 
Seven to nine weeks old WT (C57BL/6J) and Il17a-/- mice were infected with WNV at 100 PFU (i.p.) for 10 days and 
euthanized to obtain splenic CD8+ T cells. (A to D) RFC in expression of transcripts of perforin-1 (A), granzyme A (B), 
granzyme B (C), and FasL (D) in splenic CD8+ T cells or CD8-  cells from WT or Il17a-/ - mice were measured by qPCR 
(normalized to cellular β -actin mRNA). (E to F) RFC in the expressions of perforin-1 (E), and granzyme A (F) in the 
spleens of CHIKV-infected (105 PFU, i.p.) WT and Il17a-/- mice were measured on 12 d.p.i. by qPCR. Data (mean ± SEM) 
shown in A to D represent three independent experiments (n = 3 mice/group); and data in E to F represent two 
independent experiments (n = 3 mice/group). “ns” denotes no significant difference (p > 0.05). 
To test if these cytotoxicity mediators were also less expressed in other 
immune cells in Il17a-/- mice, we performed qPCR assay on CD8- splenocytes 
(mixed immune cells including NK cells) isolated from WNV-infected WT and 
Il17a-/- mice at 10 d.p.i. In contrast to the CD8+ cells, we found no difference in 
the expression of perforin-1, granzyme A, granzyme B and FasL genes in CD8- 
splenocytes from Il17a-/- mice (Fig. 4.12A-D). Whereas in WNV-infected WT 
mice, the expression of these cytotoxicity marker genes was significantly higher 
in CD8+ than CD8- cells, no such differences were detected between CD8+ and 
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CD8- cells isolated from Il17a-/- mice (Fig. 4.12A-D). In addition, there was no 
significant difference in the expression of these cytotoxicity marker genes 
between uninfected Il17a-/- and WT mice (data not shown).  
To further test whether the IL-17A-mediated cytotoxicity mediator 
expression is specific to WNV, or common across viral infections, we measured 
the expression of cytotoxicity mediator genes in WT and Il17a-/- mice infected 
with chikungunya virus (CHIKV), a single-stranded RNA virus from genus 
Alphavirus of the family Togaviridae. Similar to WNV, we found significantly 
reduced expressions of perforin-1 (Fig. 4.12E) and granzyme A (Fig. 4.12F) in 
the splenocytes isolated from CHIKV-infected Il17a-/- mice compared to WT 
controls. Collectively, these results suggest that IL-17A promotes the expression 
of the cytotoxicity mediators and facilitate CD8+ T cells cytotoxicity during WNV 
and other viral infections, such as CHIKV. 
4.13 IL-17A Induces Cytotoxic Mediators Independent of CD4+ T Cells 
The role of IL-17A in regulating the expression of cytotoxic mediators in 
CD8+ T cells has not been previously reported. To further investigate and confirm 
this, we isolated splenocytes from WNV-infected WT mice at 8 d.p.i., cultured 
them with recombinant IL-17A (50 ng/ml) ex vivo for 24 h, and measured the 
expression of perforin-1, granzyme A, granzyme B and FasL genes by qPCR 
assay. The treatment with recombinant IL-17A significantly up-regulated the 
expression of perforin-1, granzyme A, and granzyme B, but not FasL (Fig. 4.13A-
D), in the splenocytes isolated from WNV-infected WT mice. Similar results were 
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obtained when splenocytes were isolated from WNV-infected Il17a-/- mice and 
treated with recombinant IL-17A ex vivo (Fig. 4.13A-D). 
 
Figure 4.13 IL-17A promotes cytotoxic mediators independently of CD4+ cells 
Seven to nine weeks old WT (C57BL/6J) and Il17a-/- mice (n = 6 mice/group) were infected with 100 PFU (i.p.) of WNV 
and sacrificed on 8 d.p.i. to isolate splenocytes and CD8+ T cells. Splenocytes or CD4+ T cells depleted splenocytes (CD4- 
splenocytes) were cultured with or without recombinant mouse IL-17A (50 ng/ml) for 24 h ex vivo and RFC of transcripts 
of perforin-1 (A), granzyme A (B), granzyme B (C), and FasL (D) were measured by qPCR (normalized to cellular β -actin 
mRNA). All data (mean ± SEM) represent two independent experiments (n = 3 mice/group) and compared by two-tailed 
student's t-test. All data from WT and Il17a-/- mice were normalized to respective mock treated controls. 
To assess the possible role of CD4+ T cells in IL-17A-mediated expression 
of cytotoxic mediators, we depleted CD4+ T cells from the splenoocytes isolated 
from WNV-infected Il17a-/- and WT mice on 8 d.p.i., and cultured CD4- 
splenocytes with recombinant IL-17A (50 ng/ml) ex vivo for 24 h. The supply of 
recombinant IL-17A induced expression of the cytotoxic mediators even in the 
absence of CD4+ T cells (Fig. 4.13A-D), suggesting that IL-17A-mediated 
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induction of cytotoxic mediators expression in CD8+ T cell is independent of CD4+ 
T cells. 
4.14 IL-17A-induced Cytotoxicity Mediators May Involve ACT-1 Signaling 
IL-17A exerts its function through IL-17A receptor (IL-17R), which is a 
heterodimeric receptor complex of IL-17RA and IL-17RC. Although the signaling 
pathway downstream of IL-17R has not been completely understood, one 
common pathway that has been characterized is the activation of the classical 
NF-κB pathway (Gaffen, 2009; Gu et al., 2013). Upon binding to IL-17A, SEFIR 
domain of IL-17R recruits the signaling adaptor ACT-1, which further recruits an 
essential upstream activator of the classical NF-κB pathway called TRAF6 
(Gaffen, 2009). To test if IL-17A signaling in WNV-infected cells occurs via ACT-
1, we measured the expression of Act-1 in splenocytes and CD8+ T cells isolated 
from WNV-infected mice and treated ex vivo with recombinant IL-17A, as 
described above. The qPCR results showed that IL-17A treatment up-regulated 
the expression of Act-1 gene in splenocytes (Fig. 4.14A) and CD8+ T cells (Fig. 
4.14B) isolated from WNV-infected mice. 
To further test if IL-17A-mediated expression of cytotoxicity mediators 
involves NF-κB activation, we treated splenocytes isolated from WNV-infected 
WT mice with recombinant IL-17A in the presence of Bay-11-7082 (an inhibitor of 
NF-κB) and measured the expression of the cytotoxicity mediators, as described 
above. Consistent with previous reports (Huang et al., 2007; Ribaux et al., 2007), 
Bay-11-7082 inhibited the IL-17A mediated Cxcl1 expression that involves NF-κB 
pathway. However, inhibition of NF-κB did not inhibit, but interestingly further up-
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regulated the IL-17A-mediated expression of perforin-1, granzyme A, and 
granzyme B (Fig. 4.14C). These data indicate that IL-17A-mediated expression 
of cytotoxicity mediators may involve ACT-1, but may occur independently of NF-
κB pathway, which requires further investigation. 
 
Figure 4.14 IL-17A induces the expression of ACT-1 
Seven to nine weeks old WT (C57BL/6J) and Il17a-/- mice (n = 6 mice/group) were infected with 100 PFU (i.p.) of WNV 
and sacrificed on 8 d.p.i. to isolate splenocytes and CD8+ T cells. Splenocytes (A) or purified CD8+ T cells (B) were 
cultured ex vivo with or without recombinant IL-17A (rIL17A, 50 ng/ml) for 24 h, and expression (RFC) of Act-1 was by 
measured qPCR. (C) RFC of Act-1 in splenocytes cultured ex vivo for 24 h with or without rIL17A (50 ng/ml), in the 
presence of Bay-11-7082 (4 μM) or DMSO as vehicle control (< 0.05%). All data (mean ± SEM) represent two 
independent experiments (n = 3 mice/group) and compared by two-tailed student's t-test. All data from WT and Il17a-/- 
mice were normalized to respective mock treated controls. * denotes p < 0.05; ** denotes p < 0.005; and “ns” denotes not 
significant (p > 0.05). 
4.15 IL-17A Directly Induces Cytotoxic mediators in CD8+ T Cells 
IL-17R is expressed by virtually all cell types and tissues examined 
(Moseley et al., 2003; Yao et al., 1995; Yao et al., 1997). CD8+ T cells also 
express IL-17R (Lindemann et al., 2008; Yao et al., 1995), however, the 
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functional role of this receptor in CD8+ T cell biology has not yet been 
recognized. To test if IL-17A may directly promote cytotoxic mediators 
expression in CD8+ T cells, we treated CD8+ T cells purified (~ 80 to 90% pure) 
from spleens of WNV-infected WT mice with the recombinant IL-17A (50 ng/ml) 
ex vivo for 24 h, then measured expression of cytotoxicity mediators by qPCR. 
IL-17A treatment significantly induced the expression of perforin-1  (Fig. 4.15A), 
granzyme A (Fig. 4.15B), and granzyme B (Fig. 4.15C), but not FasL (Fig. 4.15D) 
in CD8+ T cells purified from WNV-infected WT mice. Similar results were also 
obtained in CD8+ T cell purified from WNV-infected Il17a-/- mice (Fig. 4.15A-D). In 
a separate experiment, we cultured splenocytes from WNV-infected Il17a-/- and 
WT mice with recombinant IL-17A (50 ng/ml) ex vivo for 24 h, separated CD8+ T 
cells from CD8- cells, and then measured expression of cytotoxic mediators by 
qPCR. Consistently, IL-17A treatment induced the expression of cytotoxic 
mediators in CD8+ T cells (data not shown), but not in CD8- cells (Fig. 4.15A-D). 
To further confirm the role of IL-17A in promoting the expression of the 
cytotoxic mediators in brain CD8+ T cells in vivo, we infected Il17a-/- mice with 
WNV (100 PFU), treated them with recombinant IL-17A (2.5 μg per mouse at day 
6 p.i.), and performed flow cytometric analysis of brain leukocytes. The results 
showed that treatment of WNV-infected Il17a-/- mice with recombinant IL-17A 
significantly induced the production of perforin and granzyme A in brain 
infiltrating CD8+ T cells (Fig. 4.15E). Taken together, these results suggest that 
IL-17A promotes the expression of cytotoxic mediator genes in CD8+ T cells 
during WNV infection in mice. 
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Figure 4.15 IL-17A directly induces cytotoxicity mediators in CD8+ T cells 
(A-D) Seven to nine weeks old WT (C57BL/6J) and Il17a-/- mice (n = 6) were infected with 100 PFU (i.p.) of 
WNV and sacrificed at 8 d.p.i. to collect spleens, followed by magnetic separation of CD8+ T cells. Relative 
fold change (RFC) of the transcripts of perforin-1 (A), granzyme A (B), granzyme B (C), and FasL (D) were 
measured in CD8+ or CD8- T cells cultured ex vivo for 24 h with or without recombinant mouse IL-17A (50 
pg/ml) by qPCR. (E) Eight week old Il17a-/- mice (n = 4 per group) infected with WNV (100 PFU, i.p.) were 
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treated with recombinant IL-17A (rIL17A, 2.5 μg/mouse) or PBS (control) via i.p. at day 6 p.i and sacrificed at 
8 p.i. to characterize brain leukocytes by flow cytometry. Mean fluorescence intensities of perforin and 
granzyme A within the gated CD45hi CD8+ cells (green) are shown in bar (right). All data (mean ± SEM) 
represent two independent experiments and compared by two-tailed student's t-test. All data from WT and 
Il17a-/- mice (shown in figures A to D) were normalized to respective mock treated controls. “ns” denotes no 
significant difference (p > 0.05). 
4.16 IL-17A Treatment Increases Survival of WNV-infected Mice 
Since CD8+ T cells are essential to clear WNV from the CNS at a later 
phase of infection, we hypothesized that recombinant IL-17A treatment in vivo 
may offer protection from WNV infection by promoting cytotoxicity of CD8+ T 
cells. To test if IL-17A may serve as a therapeutic reagent to treat WNV infection 
in mice, we infected WT female mice with WNV (100 PFU) via i.p. route. At day 6 
p.i, mice were injected with the carrier-free mouse recombinant IL-17A 
(eBioscience) or PBS as control via i.p. route for survival analysis.  
 
Figure 4.16 Recombinant IL-17A increases survival of WNV-infected mice 
WT (C57BL/6J) mice (8-week old, female) were infected with 100 PFU of WNV via i.p. route. At day 6 p.i, 
mice were injected with i.p. administration of carrier-free mouse recombinant IL-17A (rIL17A, 2.5 μg/mouse) 
or PBS. (A) Percent (%) of survival was compared using the Kaplan-Meier survival and log-rank test. Viral 
burden in brain (B) was measured by qPCR and compared by two-tailed student's t-test; “ns” denotes no 
significant difference (p > 0.05). 
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Mice that received recombinant IL-17A showed significantly increased 
survival rate compared to the PBS-treated control mice (Fig. 4.16A). Consistent 
with the survival results, mice treated with recombinant IL-17A also showed lower 
viral burden in the brain compared to the PBS-treated control mice at day 8 p.i. 
(Fig. 4.16B).  
4.17 IL-17A Induces Cytotoxicity Mediators in WNV-infected Mice 
To test if the effect of the recombinant IL-17A treatment involves a 
promotion of cytotoxicity of CD8+ T cells, we also measured the expression of the 
cytotoxicity mediators in splenic CD8+ and CD8- T cells  
 
Figure 4.17 Recombinant IL-17A induces cytotoxicity in WNV-infected mice. 
WT (C57BL/6J) mice (8-week old, female) were infected with 100 PFU of WNV via i.p. route. At day 6 p.i, mice were 
injected with i.p. administration of carrier-free mouse recombinant IL-17A (rIL17A, 2.5 μg/mouse) or PBS. (A to E) The 
transcripts of perforin-1, granzyme A, granzyme B, and FasL in splenic CD8+ and CD8- T cells (A-D), and brain (E) were 
measured by qPCR and compared by two-tailed student's t-test; “ns” denotes no significant difference (p > 0.05). 
 
0.0
0.5
1.0
1.5
P
er
fo
ri
n
-1
 R
F
C
CD8+ CD8-
p <0 .05
ns
0.0
0.5
1.0
1.5
2.0
G
ra
n
zy
m
e 
A
 R
F
C
CD8+ CD8-
p <0 .05
ns
0
1
2
3
G
ra
n
zy
m
e 
B
 R
F
C
CD8+ CD8-
p <0 .05
ns
0.0
0.5
1.0
1.5
2.0
F
a
sL
 R
F
C
CD8+ CD8-
p <0 .05
ns
rIL-17A (n=7)
PBS (n=9)
0
1
2
10
20
30
40
50
60
m
R
N
A
 R
F
C
ns
p < 0.005
p < 0.005
p < 0.005
Perforin 1 Granzyme A Granzyme B FasL
 49 
. Consistent with reduced viral burden and increased survival, 
administration of recombinant IL-17A in WNV-infected mice induced the 
expression of the cytotoxic mediators in CD8+ T cells, but not in CD8- T cells (Fig. 
4.17A-D), which agreed with our in vitro results. In addition, we also detected 
increased expression of granzyme A, granzyme B, and FasL in brain tissues of 
WNV-infected mice after IL-17A treatment (Fig. 17E). Collectively, these results 
suggest a novel and promising therapeutic role of IL-17A in facilitating WNV 
clearance by promoting CD8+ T cell cytotoxicity.  
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CHAPTER V – DISCUSSION 
This study reveals a novel role of IL-17A in facilitating WNV clearance by 
inducing the expression of cytotoxic mediator genes and promoting CD8+ T cell 
cytotoxicity. Specifically, we report here that 1) WNV induces IL-17A expression 
in both mice and humans; 2) Il17a-/- mice, generate a higher viral burden and are 
more susceptible to WNV infection; 3) CD8+ T cells purified from Il17a-/- mice are 
less cytotoxic and express lower levels of cytotoxic mediators, i.e., perforin-1, 
granzyme A, granzyme B and FasL; and most importantly; and 4) ex vivo supply 
of recombinant IL-17A as late as day 6 post-infection significantly reduces viral 
burden in the brain and increases survival rate of WNV-infected mice, suggesting 
a therapeutic potential of IL-17A. 
5.1 IL-17A Has a Protective Function in WNV Infection 
It has been previously reported that WNV mediates production of IL-23, a 
cytokine that regulate IL-17A expression (Town et al., 2009). As expected, we 
found that WNV induced IL-17A production in human and mouse in an IL-23 
dependent manner. We further found a protective function of IL-17A against 
WNV and its crucial role in clearance of WNV from brain, which was also 
consistent with function of IL-23 (Town et al., 2009). In support of our finding, it 
has been previously reported that mice depleted of IL-17A function by 
administration of anti-IL-17A antibody showed about 20% reduced survival rate 
compared to control mice after a lethal WNV challenge (Welte et al., 2011). 
However, no difference in WNV viral burden was observed between anti-IL-17A 
antibody treated and control mice (Welte et al., 2011). In contrast, our results 
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clearly demonstrate that Il17a-/- mice are more susceptible to WNV infection. The 
discrepancy between these two studies may be due to the transient effects of 
anti-IL-17A treatment when compared to complete genetic deficiency of IL-17A in 
Il17a-/- mice. More to this point, γδ-T cell produce IL-17A during early phage of 
WNV infection, whereas CD4+ Th-17 cells become the major IL-17A producer 
during the late phase of infection (Hamada et al., 2008). Thus, the administration 
of anti-IL-17A antibody at an early phase of WNV infection (0 and 5 d.p.i.) (Welte 
et al., 2011), may not have sufficiently blocked IL-17A production and its function 
during the later phase of infection. Indeed, we found that IL-17A was not 
essential for controlling the viremia on 2 d.p.i, but became critical for reducing 
viremia on 4 d.p.i and clearing the viruses from spleen and brain on 8 d.p.i.. 
Thus, it appears that IL-17A-mediated protective immunity against WNV infection 
predominantly occurs during the late phase of infection, which requires further 
investigation. 
5.2 Role of IL-17A in IFN, Cytokines and Antibody Response 
IL-17A is a pleiotropic cytokine that plays key roles during infection 
(Iwakura et al., 2008), inflammation (Park et al., 2005) and autoimmune diseases 
(Onishi and Gaffen, 2010). Further, it regulates the expression of a number of 
cytokines, including IL-1β, IFN-γ, and TNF-α (Maione et al., 2009; Song and 
Qian, 2013). Considering their critical roles in WNV pathogenesis (Ramos et al., 
2012; Shrestha et al., 2006b; Shrestha et al., 2008b; Wang et al., 2004a), it is 
plausible that IL-17A may regulate the expression of these cytokines during WNV 
infection. However, we did not detect significant differences in the expression of 
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IL-1β, IFN-γ, and TNF-α in WNV-infected Il17a-/- mice when compared to WT 
controls. These results suggest the likelihood that IL-17A-mediated protective 
immunity against WNV infection may not be associated with functions controlled 
by these cytokines. Previous studies have suggested that type I IFNs (antiviral 
cytokines), which can potently suppress IL-17A expression (Curtis et al., 2009; 
Tilg et al., 2009), play a prominent role in controlling WNV infection (Lazear et al., 
2011; Samuel and Diamond, 2005). Again, we did not detect any change in the 
expression of type I IFNs in Il17a-/- vs. WT control mice during WNV infection. 
Moreover, IL-17A has been suggested to regulate the humoral immune response 
(Grund et al., 2012; Tarlinton, 2008; Yuan et al., 2010), however, we did not see 
such effect during WNV infection in mice. Despite unaltered inflammatory 
response, type I IFN expression and humoral immune response, Il17a-/- mice 
generated higher viral burden, suggesting that IL-17A mediated protective 
immunity during WNV infection is independent of these immune responses. 
5.3 Role of IL-17A in Leukocyte Homing to CNS 
WNV invades the CNS and infects neurons and CNS-resident cells, such 
as microglia and astrocytes, which leads to production of cytokines and 
chemokines that recruit peripheral leukocytes into the brain (Glass et al., 2005; 
Hussmann and Fredericksen, 2014; Shrestha and Diamond, 2004; Town et al., 
2009). We previously reported that IL-23 has an important role in recruiting 
CD11b+ monocytes and macrophages into the CNS to control WNV infection 
(Town et al., 2009). Considering the role of IL-23 in producing IL-17A, and the 
role of both of these cytokines in inducing and sustaining leukocyte recruitment to 
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infected sites (Roussel et al., 2010; Shahrara et al., 2009), we hypothesized that 
leukocyte migration into the CNS would be reduced in Il17a-/- mice. Surprisingly, 
we detected a modestly elevated leukocyte influx into WNV-infected Il17a-/- 
mouse brains by both flow cytometry and confocal microscopy. 
In dissecting the mechanism, we found that the expression of CCL5 was 
elevated in both the CNS and the peripheral tissues of WNV-infected Il17a-/- mice 
compared to WT controls. CCL5 plays a protective role in WNV, influenza and 
parainfluenza infections by promoting leukocyte trafficking to infected tissues 
(Glass et al., 2005; Kohlmeier et al., 2008). Also, Ccl5 expression sustains CD8+ 
T cell responses during influenza (Kohlmeier et al., 2008), parainfluenza 
(Kohlmeier et al., 2008) and chronic lymphocytic choriomeningitis virus (LCMV) 
(Crawford et al., 2011) infections. The up-regulation of Ccl5 in Il17a-/- mice may 
be due to several reasons. First, the higher viral load in Il17a-/- mice could trigger 
a stronger Ccl5 expression (Matsukura et al., 1998; Saito et al., 1997). Secondly, 
the presence of IL-17A in WT mice may suppress Ccl5 expression, since IL-17A 
can down-regulate Ccl5 expression (Andoh et al., 2002; Shen et al., 2005). 
Although increased Ccl5 expression may account for modest elevation in brain 
infiltrating leukocytes in Il17a-/- mice, this did not result in protection of these mice 
from WNV infection, implying a possible functional defect in brain infiltrating 
effector leukocytes in Il17a-/- mice. 
5.4 IL-17A Regulates CD8+ T Cell Cytotoxicity 
CD8+ T cells play a critical role in clearance of viruses from the CNS 
(Binder and Griffin, 2001; Griffin, 2010; Shrestha and Diamond, 2004). CD8+ T 
 54 
cells can control viral infection directly by inducing apoptosis of virus-infected 
cells via perforin, granzyme, or Fas-FasL interactions (Harty and Badovinac, 
2002; Shresta et al., 1998), or indirectly by immune-mediated non-cytolytic 
clearance of viruses from neurons by producing cytokines, such as TNF-α and 
IFN-γ (Binder and Griffin, 2001; Griffin, 2010). Mice deficient in the expression of 
cytotoxic mediators such as perforin, FasL, or cytokines, such as TNF-α and IFN-
γ, exhibit increased mortality and viral burden in the CNS and peripheral organs 
following WNV infection (Shrestha and Diamond, 2007; Shrestha et al., 2012; 
Shrestha et al., 2006a; Shrestha et al., 2006b; Shrestha et al., 2008b; Wang et 
al., 2004b). However, we did not detect any significant difference in the 
expression of the cytokines including TNF-α and IFN-γ between WNV-infected 
WT and Il17a-/- mice, suggesting that IL-17A-mediated control of WNV by CD8+ T 
cells may occur independently of the effects of these cytokines. We found that 
CD8+ T cells isolated from Il17a-/- mice have significantly reduced cytotoxicity 
compared to WT controls, which may explain higher viral burden and lower 
survival rates of Il17a-/- mice, despite elevated leukocyte infiltration (including 
CD8+ T cells) into the CNS. While we are not certain whether CD8+ T cells 
predominantly contribute to WNV clearance by causing cytolysis of WNV-infected 
neurons due to lower MHC I expression in these cells (Kimura and Griffin, 2000; 
Mucke and Oldstone, 1992), it is likely that CD8+ T cells can cause cytolysis of 
WNV-infected non-neural cells, such as infiltrating macrophages and neutrophils, 
and microglia in the CNS, thus facilitating the virus clearance (Bai et al., 2010; 
Shrestha and Diamond, 2004, 2007; Shrestha et al., 2006a). In line with reduced 
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cytotoxicity, CD8+ T cells from Il17a-/- mice had significantly reduced expression 
of perforin-1, granzyme A, granzyme B and FasL in most of the tissue examined 
during WNV infection. Although NK cells (type of CD8- cells) also express these 
genes and mediate apoptosis of target cell, we did not detect difference in 
expression of cytotoxic mediators in CD8 negative (CD8-) cell populations 
isolated from WNV-infected WT and Il17a-/- mouse spleens. This indicates that 
NK cells (type of CD8- cells) may not play a prominent role in IL-17A-mediated 
cytotoxicity during WNV infection. This notion is consistent with the previous 
reports that NK cells have a little or no role in controlling WNV infection (Shrestha 
et al., 2006a). 
It is worthy to note that CD8+ T cells have also been shown an 
immunopathological role when mice were infected intravenously with a high dose 
(108 PFU) of WNV (Sarafend strain), resulting in 100% mortality with a 6-day 
mean survival time (Wang et al., 2003). However, such an immunopathology role 
of CD8+ T cells was likely not due to their cytotoxic functions because these cells 
are usually activated after one week post-infection. In support of this, that same 
study and many other reports also showed a recovery role of CD8+ T cells when 
mice were infected with low doses (102-103 PFU) of WNV, which is similar to the 
current study (Brien et al., 2011; Brien et al., 2007; Shrestha et al., 2008a; 
Shrestha et al., 2012; Shrestha et al., 2006a; Wang et al., 2003). In addition, 
Th17 cells and IL-17A have been implicated in inflammation and 
immunopathology associated with autoimmune diseases (McFarland and Martin, 
2007; van den Berg and Miossec, 2009; Zepp et al., 2011) and some virus-
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induced chronic CNS diseases (Hou et al., 2014; Hou et al., 2009; Savarin et al., 
2012), suggesting that Th-17/IL-17A axis may have different implications in such 
immunopathological and chronic inflammatory conditions. 
5.5 IL-17A Has a Potential Therapeutic Role Against WNV 
Our data demonstrates that IL-17A deficiency leads to an attenuated CD8+ 
T cell cytotoxicity and deficient WNV clearance. Both CD4+ Th-17 cells and γδ T 
cells, the major cells that produce IL-17A, have been previously shown to 
promote CD8+ T cell cytotoxicity during infection (Hamada et al., 2009; Xu et al., 
2010), autoimmune disease (Ankathatti Munegowda et al., 2011a), and cancers 
(Ankathatti Munegowda et al., 2011b; Martin-Orozco et al., 2009). Also, NK cells 
treated with IL-17A overexpress perforin and granzymes, and have better 
cytotoxic functions (Al Omar et al., 2013), which provides additional evidence that 
IL-17A signaling can induce the expression of cytotoxicity mediators. These 
reports support our finding and suggest that IL-17A may facilitate cytotoxicity of 
CD8+ T cells in diverse disease conditions. 
Various types of immune cells, such as CD4+ Th-17 cells, γδ-T cells, NKT 
cells, and CD8+ T cells can produce IL-17A (Gu et al., 2013; Welte et al., 2011). 
In addition, the IL-17A receptor (IL-17R) is expressed ubiquitously in virtually all 
cell types and tissues examined (Andoh et al., 2002; Moseley et al., 2003; Yao et 
al., 1997). Although CD8+ T cells can produce IL-17A and also express its 
cognate receptor (Lindemann et al., 2008; Yao et al., 1995), the link between IL-
17A and CD8+ T cell cytotoxic function has not been previously recognized. In 
theory, it is possible that IL-17A may affect CD8+ T cell development and/or 
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function either by directly acting on these cells or indirectly through other cell 
types. Since we found similar levels of CD8+ T cells and CD4+/CD8+ ratios in 
splenocytes isolated from Il17a-/- and WT mice infected with WNV, it appears that 
CD8+ T cell development remains unaltered in Il17a-/- mice and IL-17A may 
largely control CD8+ T cell function during WNV infection. This hypothesis is 
confirmed by ex vivo treatment of IL-17A to splenocytes isolated from WNV-
infected Il17a-/- and WT mice, which showed an up-regulation of perforin-1, 
granzyme A, and granzyme B expression in CD8+ T cells by IL-17A, in a CD4+ T 
cell-independent manner. These results suggest that IL-17A can induce the 
expression of cytotoxic mediators by directly acting on CD8+ T cells. However, 
the induction of FasL by recombinant IL-17A was differentially affected in our 
experiments. For instance, in vitro IL-17A treatment did not induce the 
expression of FasL in CD8+ T cells, while it was induced after in vivo 
administration of IL-17A. This discrepancy is likely due to the experimental 
conditions or may reflect differential role of IL-17A in regulating the expression of 
these cytotoxic mediators, which requires further investigation. We further 
demonstrated that the treatment of WNV-infected Il17a-/- mice with recombinant 
IL-17A significantly induced the production of perforin and granzyme A in brain 
infiltrating CD8+ T cells, which confirmed the role of IL-17A in promoting the 
expression of the cytotoxic mediators in brain infiltrating CD8+ T cells in vivo. 
To extend upon our finding, we tested therapeutic potential of IL-17A in a 
mouse model of WNV infection. Importantly, administration of a single dose of 
recombinant IL-17A to WNV-infected mice, even as late as day 6 p.i., induced 
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the expression of cytotoxic mediators in CD8+ T cells, dramatically reduced viral 
burden in the brain, and significantly increased survival rate, suggesting a 
promising therapeutic role of IL-17A against WNV infection. 
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CHAPTER VI – CONCLUSION AND FUTURE DIRECTIONS 
6.1 Conclusion 
IL-17A and CD8+ T cells regulate diverse immune functions during 
microbial infections, malignancies, and autoimmune diseases. IL-17A is a 
proinflammatory cytokine produced by diverse cell types, while the CD8+ T cells 
(known as cytotoxic T cells) are major cells that provide immunity against 
intracellular pathogens. Previous studies have demonstrated a crucial role of 
CD8+ T cells in recovery from WNV infection. Here, we demonstrate that IL-17A 
protects mice from lethal WNV infection by promoting CD8+ T-cell-mediated 
clearance of WNV. In addition, treatment of WNV-infected mice with recombinant 
IL-17A reduces viral burden and increases survival of mice, suggesting a 
potential therapeutic. In conclusion, this study uncovers a novel function of IL-
17A in promoting CD8+ T cell cytotoxicity during WNV infection in mice. This 
novel IL-17A-CD8+ T cell axis may also have broad implications in immunity to 
other microbial infections and cancers, where CD8+ T cell functions are crucial. 
6.2 Future Directions 
In this study, we found the production of IL-17A in WNV-infected human 
and mice, which we also confirmed in a mixed culture of human and mouse 
immune cells infected in vitro with WNV. We further demonstrated a novel 
function of IL-17A in promoting the cytotoxicity of CD8+ T cell against WNV 
infection. In addition, a supply of recombinant IL-17A to a culture of CD8+ T cells 
and WNV-infected mice clearly induced the expression of cytotoxicity mediator 
genes. The role of IL-17A in promoting the expression of cytotoxic mediators in 
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CD8+ T cells has not been previously reported and the signaling mechanism by 
which IL-17A regulates the expression of cytotoxicity mediators is not currently 
understood. In addition, diverse cell types including immune cells, astrocytes, 
and microglia can produce IL-17A and express IL-17A receptor. Future studies 
are required for characterization of IL-17A producing and responding cells in both 
CNS and periphery during various stage of WNV infection. In addition, a better 
understanding of the regulation of IL-17A production and dissection of the 
signaling mechanism by which IL-17A induces expression of cytotoxicity 
mediators and promotes CD8+ T cell cytotoxicity in the context of WNV and other 
diseases may help to exploit novel IL-17A-based therapeutic strategies. 
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